Johnson & Johnson is now a pharmaceutical and medtech company after spinning off its consumer brands as Kenvue in 2023. The general approach is in the stock courses.
Two Franchises, One Docket
Johnson & Johnson after Kenvue is a medical-device company glued to a pharmaceutical company. Medtech (surgery, ortho, vision, interventional) is procedure-cycle and hospital-capex. Innovative Medicine is patent clocks, immunology, oncology, and neuroscience. Litigation (talc and the rest) is a third object that can reprice the equity without a product miss.
Education only. Not medical advice. Size JNJ as a healthcare mega-cap with legal and LOE gaps, not as a defensive cereal stock.
1. Band-Aids to Kenvue and medtech
Band-Aid and baby powder built the consumer myth. The trading-relevant firm is the one that bought and built device platforms and a pharma pipeline, then spun the consumer brands so the remaining equity could try for a higher multiple. The spin did not spin off the talc docket.
Stelara’s loss of exclusivity is a case study in how a cash cow becomes a hole. Biosimilars do not need to “kill” a franchise to compress the multiple. They only need to take net price. The replacement portfolio has to show up in the 10-K, not in a keynote adjective.
Device quality events (a recall, a warning letter, a competitor’s safer label) hit with a different lag than a failed trial. Hospital procedure volumes hit with a third lag. Do not average them.
2. What the modern company sells
MedTech: surgery, orthopaedics, interventional solutions, vision. Innovative Medicine: oncology, immunology, neuroscience, pulmonary. Two reporting lines. Two competitive sets. One ticker.
Hospital capital budgets correlate with rates and with elective-procedure recovery. A “defensive healthcare” label does not survive a procedure recession.
Compare pipeline concentration to Lilly’s incretin dominance only to remember that JNJ is not that object. JNJ is broader and slower. Broader is not safer if you paid for Lilly-like growth. Merck depends heavily on one drug; J&J spreads its risk across many drugs and devices, though talc litigation adds a risk Merck does not carry.
3. Why it still compounds — and what stops it
Surgeon switching costs, scale manufacturing, and a still-deep pipeline bench are the moat. Dockets and LOE clocks are the holes. Holes can be priced. Denial cannot.
What stops compounding: a clustered LOE without replacement, a device quality event that lasts more than a quarter, or a legal reserve that actually changes capital return.
JNJ can remain a cash compounder and a crowded “quality” long at the same time. Crowding is an input.
4. How traders actually use the ticker
JNJ is quieter than LLY and still gaps on verdicts, FDA, and guidance. Size as healthcare with a legal tail, not as a utility. JNJ is a defensive name but still gaps on litigation rulings and drug news, so set size with the position size calculator. Court decisions have produced volume on the stock scanner outside earnings season.
Illustration: $58,000 in the account and $580 at risk with a $8 stop under $175 means about 72 shares. Set that down in a written trading plan; the risk rules matter just as much for defensive stocks.
Pairs vs other large pharma only with a pipeline or LOE view.
5. Mistakes, limits, takeaways
Mistakes: treating the consumer myth as the business; ignoring LOE; using “defensive” as a size multiplier. Innovative Medicine versus MedTech sales, and the loss of exclusivity on Stelara, are the lines to track. The statements course covers segment reading; for the very basics see What Is Stock Trading?
Not medical advice. Labels, trials, and dockets change. Educational only.
Worth remembering
- Medtech and pharma are different cycles.
- Loss of exclusivity runs on a calendar. Know the dates.
- Litigation can reprice without a product miss.
- Size for a verdict gap.
J&J's diversification lowers the odds of a single-product shock, but litigation is the exception to watch. Educational only. Not tax, legal, or a recommendation to buy, sell, or hold JNJ.